After 25 years at the pharma giant Roche, the drug hunter Martin Stahl is leaving to join a biotech. CAMBRIDGE, Massachusetts — A longtime drug-hunting veteran is leaving one of the largest drugmakers to lead the science division at the biotech startup LifeMine Therapeutics, Insider has learned. FogPharmaThe big draw for Stahl was LifeMine's approach to discovering drugs. With its genetic-database approach, LifeMine hopes to greatly speed up how long it takes to develop fungi-derived drugs. Stahl said LifeMine's approach leaned on nature, rather than medicinal chemists, to design the drugs.

---